CTT Pharma signs LOI for US clinical trials of nicotine products

CTT PHARMACEUTICAL HLDGS INC

CTT PHARMACEUTICAL HLDGS INC

CTTH

0.00
  • CTT Pharmaceutical Holdings signed a non-binding letter of intent with a US company to run clinical trials and testing for potential nicotine products.
  • The proposed partnership would support an independent US market launch using CTT’s patented technology.
  • CTT said it will provide updates as additional information becomes available.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CTT Pharmaceutical Holdings Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202606170600ACCESSWRNAPR_____1178141) on June 17, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.